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Global protein expression proﬁling can potentially uncover perturbations associated with
common forms of heart disease. We have used shotgun MS/MS to monitor the state of
biological systems in cardiac tissue correlating with disease onset, cardiac insufﬁciency and
progression to heart failure in a time-course mouse model of dilated cardiomyopathy.
However, interpreting the functional signiﬁcance of the hundreds of differentially expressed
proteins has been challenging. Here, we utilize improved enrichment statistical methods and
an extensive collection of functionally related gene sets, gaining a more comprehensive
understanding of the progressive alterations associated with functional decline in dilated
cardiomyopathy. We visualize the enrichment results as an Enrichment Map, where signif-
icant gene sets are grouped based on annotation similarity. This approach vastly simpliﬁes
the interpretation of the large number of enriched gene sets found. For pathways of speciﬁc
interest, such as Apoptosis and the MAPK (mitogen-activated protein kinase) cascade, we
performed a more detailed analysis of the underlying signaling network, including experi-
mental validation of expression patterns.
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Cardiomyopathy / Gene expression / MS / Pathway analysis / Quantitation / Systems
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1 Introduction
Heart disease is a leading cause of death, accounting for
430% of all deaths in 2005 in the US alone [1]. In parti-
cular, heart failure stemming from diverse etiologies,
including hypertension, long-term consequences of
myocardial infarction, viral infection and genetic disorders,
is an emerging epidemic [2]. Although treatable, heart fail-
ure is often referred to as a silent killer since patients are
diagnosed at an end-stage when it is too late to reverse the
pathology. Finding molecular signatures to detect heart
failure at an early, treatable stage prior to clinical presenta-
tion is vital to improving long-term survival outcomes.
However, uncovering the causative mechanisms and
predictive biomarkers remains a daunting task [3, 4] due to
the complexity of disease development.
MS/MS-based proteomic proﬁling is a promising
approach for characterizing protein perturbations associated
with cardiac disease [5, 6]. In dilated cardiomyopathy
(DCM), the ventricle walls stretch and thin out causing the
heart to enlarge and fail. In a recent study of a mouse
phospholamban transgenic mutant model (PLN-R9C) of
DCM [7], we used exhaustive shotgun sequencing to
examine quantitative changes in global protein expression
Abbreviations: DCM, dilated cardiomyopathy; GO, Gene Ontol-
ogy; GSEA, Gene Set Enrichment Analysis; MAPK, mitogen-
activated protein kinase; ORA, over-representation analysis
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points representing discernible clinical phenotypes (early,
mid-, and end stages) along the trajectory to overt cardiac
failure. A generalized linear model identiﬁed 593 proteins
signiﬁcantly differentially up- or down-regulated across
three time points in PLN-R9C mice relative to normal
control littermates. This list was reﬂective of a shift in
energy metabolism, and activation of speciﬁc cellular stress
response cascades that lead to apoptotic signaling [8–10].
However, by focusing on the most differentially expressed
proteins across all time points simultaneously, only a partial
list of the strongest biological signals was detected. New
analysis methods are required to study stage-speciﬁc
differences in expression accompanying disease progression
and weaker, but still important, signals.
Transcriptomic datasets are traditionally analyzed by
scoring gene expression differentiality (e.g. between disease
and healthy states) after normalization of the raw mRNA
expression data using statistical methods that consider
technical noise and biological variability [11]. Candidate
genes are then deﬁned by setting a threshold on some
measure of differential expression [12]. Since biological
responses tend to be functionally coherent, over-repre-
sentation analysis (ORA) can be used to detect statistically
signiﬁcant differential expression of functionally related
‘‘gene sets’’ [12]. A ‘‘gene set’’ is a collection of genes
deﬁned a priori that share some attribute or feature such as
annotation to a common pathway (e.g. cell cycle or insulin
signaling). The resulting list of affected gene sets is often
biologically more intuitive than the larger lists of differential
genes. Numerous software tools are available to perform
ORA [12], including FunSpec [13], GoMiner [14], FatiGO
[15], DAVID [16], BiNGO [17] and ErmineJ [18]. Most ORA
tools typically only use Gene Ontology (GO) annotation [19]
as a convenient source of gene sets, though some are being
adapted to exploit more detailed network-level information
(i.e. gene–gene interactions) that is increasingly available
[12, 20].
While we used ORA previously to ﬁnd alterations in
stress responses and metabolism that may underlie tissue
remodeling and ﬁbrosis in our DCM model, we only
considered the most differentially expressed gene products
and hypothesize that we have overlooked a wealth of addi-
tional more subtle and stage-speciﬁc biologically interesting
patterns. To address this, we used the Gene Set Enrichment
Analysis (GSEA) method [21] to perform ORA on all of the
available expression value changes. GSEA analyzes a rank-
ing of gene products according to a differentiality statistic
(e.g. ratio of expression in disease versus control). Gene sets
are then tested to see if members lie more toward the top or
bottom of the ranking than expected by chance alone (i.e.
majority of members of a gene set are coordinately up- or
down-regulated). Thus, we expect to uncover additional
biological trends in our PLN-R9C data using this method
because it considers all genes, not just the top most differ-
ential, and can ﬁnd signiﬁcant and coordinated expression
patterns at the gene set level even if the expression of the
genes within the set is weak.
To aid in the interpretation of our GSEA analysis, we
developed a method, Enrichment Map, to intuitively visua-
lize and compare the results across time
points. In comparison with our initial published
study [7], adoption of a more powerful enrichment test
together with a simpliﬁed graphical organization
of the results enabled the identiﬁcation of additional
biologically relevant perturbations associated with DCM. For
pathways of speciﬁc interest we performed a more
detailed analysis, explicitly considering the underlying
signaling network and experimentally validating expression
patterns.
2 Materials and methods
2.1 Protein samples and quantiﬁcation
We used proteomics data from our previously published
PLN-R9C DCM study [7]. Brieﬂy, this data was collected
from cardiac protein extracts collected from pooled ventricle
tissue obtained from two distinct strains of mice, one a
transgenic model expressing a dominant Arginine to
Cysteine point mutation at position 9 in the phospholamban
protein, which results in the presentation of DCM pheno-
typically similar to the human condition [22], and the other
healthy littermates (strain FVB/N) as a control. Three time
points were proﬁled, representing early-stage (8wk), mid-
stage (16wk) and end-stage (24wk) disease [7]. Six thousand
one hundered and ninety high stringency proteins were
identiﬁed by nanoelectrospray LC-MS/MS and quantiﬁed by
spectral counting [23]. The spectral count mapping to a
particular protein was summed to generate a total count per
protein per sample. We supplemented our original data with
1072 proteins that were detected by MS but previously
discarded because they were detected with only a single
unique high conﬁdence peptide. This re-analysis was moti-
vated by the discovery that most of these represent small,
but biologically important proteins (e.g. brain natriuretic
peptide, a 121 amino acid protein that is a validated
biomarker of heart failure [24]). This resulted in a list of
7262 proteins used for the current analysis. To correct for
length bias, i.e. larger proteins produce more peptides and
so tend toward higher counts, the counts were divided by the
number of expected tryptic peptides in a similar fashion as
described by Lu et al. [25]. Protein counts were further
normalized across all experiments using local polynomial
regression ﬁtting (Lowess) to adjust for residual differences
[7]. As we now account for protein length during normal-
ization by dividing spectral counts by the expected number
of observable peptides for each individual protein, the
weight of proteins with a larger than expected number of
observable peptides was relatively reduced and those from
smaller proteins increased. This allowed us to apply more
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nevertheless important in signal transduction and other
pathways that may be perturbed during the development of
DCM.
2.2 GSEA analysis
We used GSEA [21] to compute gene set enrichment after
ranking proteins by differential expression in disease versus
control. Traditional transcriptomics analysis uses various
statistical tests to compare the two phenotypic classes
including ‘‘signal-to-noise,’’ ‘‘t-test’’ and ‘‘ratio of classes,’’
but these standard tests assume the data are normally
distributed whereas our R9C proteomics data are not, due to
the under sampling nature of MS/MS spectral counting [26].
We also wanted to use a statistic that indicates directionality,
i.e. whether the protein is up- or down-regulated. Thus, we
used the non-parametric KS test to rank the proteins
because it makes no assumptions as to the underlying data
distribution and is signed. Using this statistic, 164 proteins
were signiﬁcantly (p-valueo0.05) differentially expressed at
the early stage (8wk), of which 69 proteins were putatively
up-regulated and 95 proteins were down-regulated, while
652 proteins were signiﬁcantly affected at the mid-stage
(16wk), of which 495 proteins were putatively up-regulated
and 157 proteins were down-regulated. However, all
proteins are ranked and input into GSEA.
GSEA was run using gene sets from diverse public
sources (described below). Small (o515 genes) gene sets
were removed because these are more likely to appear
signiﬁcant by chance alone. Large (4500 genes) gene sets
were removed because they are typically too general to
usefully interpret. Filtering has the added beneﬁt of redu-
cing the problem of false discovery by multiple testing. For
each analysis, 1000 gene set permutations were used to
compute a false-discovery rate.
2.3 Gene set collection
GO annotation was collected from the August 2008 down-
load of the org.Mm.edGO2ALLEGS Bioconductor package.
GO annotation was up-propagated so that all genes anno-
tated to children terms were also assigned to the parent
terms and genes were mapped to Entrez Gene identiﬁers.
All available GO annotations were used to maximize gene
coverage. To further improve gene coverage, we also
collected all available BioPAX formatted pathways from
Reactome [27], HumanCyc [28], National Cancer Institute
Pathway Interaction Database [29], Integrating Network
Objects with Hierarchies Pathway Database (www.inoh.org),
Biocarta (www.biocarta.com), Cellmap (cancer.cellmap.org)
and Netpath (www.netpath.org). BioPAX is a standard data
exchange format for pathway information (www.biopax.org).
Additional curated gene sets were collected from the Mole-
cular Signatures Database [21], the comprehensive Resource
of Mammalian protein complexes [30] and Disease Hub
(http://zldev.ccbr.utoronto.ca/ddong/diseaseHub/). Since
the pathway resources, except Reactome, provide human
pathway information only, putative mouse homologs were
cross-mapped based on orthology (ftp://ftp.informatics.jax.-
org/pub/reports/HMD_HGNC_Accession.rpt). Conversion
tables for RefSeq and Uniprot to human Entrez Gene were
downloaded from Biomart [31].
2.4 Enrichment Map analysis
To increase the power and coverage of our analysis, we
collected gene sets from multiple independent sources (see
above). Unfortunately, this also increases the number of
redundant or similar gene sets, which complicates inter-
pretation of results. To overcome this challenge, we devel-
oped a novel visualization approach, Enrichment Map,
which organizes gene sets in a more intuitive way and
which is implemented as a plugin for the Cytoscape network
analysis environment [32]. Enrichment Map places similar
gene sets near each other, which results in a more concise
global view of enriched biological functions (many gene sets
related to the same function are grouped, which simpliﬁes
their display). This map is a network of gene sets in which
the nodes (circles) represent statistically signiﬁcant terms
and the links (edges) the degree of gene set overlap (i.e.
multiple gene sets containing the same genes). An auto-
mated layout algorithm is used to place connected (i.e.
similar) gene sets close together as clusters of terms
describing related pathways, cellular processes or functions.
Gene sets are linked if their overlap coefﬁcient is 40.5 (i.e.
gene sets share 50% or more genes). Software to construct
and browse Enrichment Map is freely available (http://
www.baderlab.org/Software/EnrichmentMap) (Merico, D.,
Isserlin, R., Stueker, O., Emili, A., Bader, G. D., Enrichment
Map: A network-based method for gene-set enrichment
visualization and interpretaion. 2010, submitted).
3 Results
3.1 Differentially expressed gene sets in DCM
preceding heart failure
The PLN-R9C mutant heart has a calcium ﬂux imbalance
due to the mutant (R9C) form of phospholamban which
constitutively inhibits the SERCA ATPase responsible for
calcium ion transport from the cytosol into the sarcoplasmic
reticulum in muscle [22], which eventually leads to heart
failure. In an effort to gain clinically useful insights into the
causative basis of heart failure from the diverse proteomics
patterns generated as part of our ongoing DCM proﬁling
initiative [7, 33–35], we developed a computational analysis
workﬂow for interpreting global protein abundance data that
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Figure 1. Enrichment analysis workﬂow. Outline of the processing of information from MS/MS data to Enrichment Map. First, spectral
counts measured for each identiﬁed protein at two time points (early and mid-stage) in the PLN-R9C cardiovascular disease model and the
healthy (wild-type) control [7] were normalized and ranked by p-value. The ranked protein list was then examined for signiﬁcant over-
representation of gene sets using the threshold-free technique of Gene Set Enrichment Analysis (GSEA). Gene sets were collected from a
diverse set of public databases. Finally, the enrichment results were visualized to enable easy manual detection of global trends and
hypothesis generation. A node in the Enrichment Map represents a gene set. Node color intensity represents the enrichment signiﬁcance
and the hue (blue/red) indicates whether a particular gene set is up- or down-regulated. Node size represents the gene set size and line
thickness shows the degree of overlap (shared genes) between the two gene sets it connects. Two different enrichment experiments were
simultaneously visualized to compare the enrichment results of the early- and mid-disease stages by mapping early-stage results to the
node center (inner part) and mid-stage results to the node border (outer part).
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ment analysis with an efﬁcient graphical summary display
for exploratory visualization (Fig. 1).
To generate ranked lists of differentially expressed
proteins between the disease (i.e. PLN-R9C) and healthy
(i.e. wild-type) hearts for analysis using our workﬂow, we
normalized and scored our previously published mouse
heart tissue protein abundance proﬁles, measured as spec-
tral counts mapped with high conﬁdence to cognate
proteins by MS/MS (see Section 2). We then applied GSEA
[21] to ﬁnd gene sets that are enriched in differentially
expressed proteins (see Section 2). To maximize protein
coverage, we collected curated gene sets from 11 public
repositories containing gene function annotations, path-
ways, protein complexes and disease signatures (Table 1).
We focused our analysis on the patterns of differential
protein expression at the two earliest time points available
(8 and 16 wk) to uncover early- (i.e. pre-symptomatic) and
mid-stage (i.e. clear evidence of cardiac functional defects
but minimal morbidity) effects. This is in contrast to our
original linear model analysis [7],] which resulted
a set of proteins differentially expressed across all three time
points at once. Our re-analysis resulted in a marked
improvement in both the variety and amount of signiﬁcant
gene sets that was returned compared to our original study
[7]. We found 266 enriched gene sets (p-valueo0.01, false-
discovery rateo0.1) for the early and mid-stages, compared
to the 27 reported in the original paper (p-valueo0.01) [7].
This tenfold increase is presumably due to the
increased number of gene sets used, the analysis of each
time point separately (different enriched gene sets resulted
at each time point) and the ability of GSEA to identify gene
sets with weak, but coordinated, expression patterns [21].
The original analysis identiﬁed an increase in
cytoskeleton processes, muscle development, ER stress,
protein degradation, unfolded protein response and apop-
tosis and a decrease in aerobic respiration and
heart development, matching the DCM phenotype [7]. Our
analysis found all of these processes and many more, some
of which are differentially perturbed at only one time
point, including cell growth, immunity, translation, RNA
processing, and more detailed views of metabolism and
signaling.
3.2 Enrichment Map visualization of global
perturbations
To deﬁne a more concise picture of the pathways that are
induced during the disease course, we visualized the early
and mid-stage results as an Enrichment Map (see Section 2).
A single integrated Enrichment Map was used to display the
enrichment analysis results for both early- and mid-stage
disease allowing direct comparison of the time points
(Fig. 2) (Enrichment Map Cytoscape session available in
Supporting Information at http://www.baderlab.org/Data/
R9cEM). The node center (inner circle) color represents the
enrichment obtained for the early time point, while the node
border (outer circle) color reports the results for the mid-
time point. From this diagram, it was easy to identify both
similarities in the two time points, such as the uniform up-
regulation of the actin remodeling machinery and protein
translation (completely red circles) together with uniform
down-regulation of the citric acid cycle (completely blue
circles), and differences, such as the strong up-regulation of
apoptosis, proteasome and RNA processing/splicing appa-
ratus at the mid-stage (circles where one part is white and
the other is colored). These differences likely represent a
physiological response of the cardiomyocytes during the
disease progression. For instance, the changes in energy
metabolism (glycolysis, citric acid cycle and NADH dehy-
drogenase) shows evidence of a known shift in energy usage
from more efﬁcient aerobic respiration at early stage to less
efﬁcient anaerobic respiration at later stages, reminiscent of
the Warburg effect seen in fast growing cancer cells [36].
This also shows a limitation of our analysis, as energy
Table 1. Publicly accessible curated gene set sources used in this study
Source URL Version
Reactome http://www.reactome.org Version 27 (December 2008)
Cancer Cell Map http://cancer.cellmap.org/cellmap May 22, 2006
Net Path http://www.netpath.org April 29, 2008
Integrating Network Objects with
Hierarchies (INOH)
http://www.inoh.org November 28, 2007
BioCyc http://biocyc.org March 9, 2009
NCI Pathway Interaction Database http://pid.nci.nih.gov/PID/index.shtml October 20, 2009
NCI Biocarta http://pid.nci.nih.gov/PID/index.shtml June 1, 2004
Molecular Signal Database (MSigDB) -
c2 (pathways)
http://www.broad.mit.edu/gsea/msigdb Version 2.5 (April 7, 2008)
Gene Ontology (GO) http://www.bioconductor.org/packages/2.5/
data/annotation/html/org.Mm.eg.db.html
August 2008
Disease Phenotypes http://www.utoronto.ca/zhanglab/index.html
Corum Mips Complexes http://mips.gsf.de/genre/proj/corum February 13, 2008
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factors, including intracellular calcium, which is increased
in PLN-R9C. Some of the changes (citric acid cycle) are
expected, whereas others require more follow-up (initial
glycolysis down-regulation, NADH and ATP synthase up-
regulation). Up-regulation of many processes, including
protein translation and RNA processing/splicing, are
consistent with compensatory cardiomyocyte growth,
associated with cardiac distension. By mid-stage, the effects
of these stress responses appear to become detrimental,
with the PLN-R9C mouse displaying extensive thinning of
the ventricular wall, presumably due to an extensive loss of
cardiomyocytes [7].
A novelty compared to our previous study is the differ-
ence in time-behavior of multiple processes, such as cytos-
keleton control pathways. Changes in the sarcomere
structure, the main contractile apparatus of the myocyte, are
known to be preceded by actin remodeling [37]. Actin-based
cytoskeletal mobilization ultimately leads to cardiac remo-
deling [38], which is clinically evident as an enlarged
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Figure 2. Processes perturbed in early- versus mid-stage DCM. Enrichment Map representation of the GSEA results obtained for the PLN-
R9C transgenic mouse model of DCM versus wild type littermate controls at an early stage (8wk, pre-symptomatic) and mid-stage (16wk,
reduced cardiac function but minimal morbidity) of heart disease. The inner circle is colored according to early stage onset, and the outer
circle according to mid-stage disease. Node color and shading intensity represents the statistical signiﬁcance of enrichment of a particular
gene set.
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tion (reduced fractional shortening and contraction force)
[38]. From the Enrichment Map, we see a consistent up-
regulation of actin remodeling machinery at early- and mid-
stage disease, whereas microtubule and sarcomeric up-
regulation is only present at mid-stage disease. This high-
lights a potential difference in timing or coordination
of these remodeling processes. Thus, the Enrichment Map
signiﬁcantly eases visual comparison of global trends
in major cellular systems as a function of disease
progression.
3.3 Exploring the apoptotic network
The enrichment map clearly showed apoptosis as a key
element in the transition from an early-stage compensatory
hypertrophy response (i.e. enhancing cardiac output) to mid-
stage dilation, which precedes ﬁbrosis and ultimately heart
failure [8]. Since many of the enriched gene sets originally
came from pathway databases, which curate detailed protein
interaction relationships, we were able to create a network
view of the enriched apoptosis gene set from the Reactome
pathway database, showing differential protein expression,
using Cytoscape [32] (Fig. 3). Given that the transgenic PLN-
R9C model has disrupted calcium ﬂux within myocytes, an
interesting active molecule in the pathway, gelsolin, stood
out (Fig. 3). Gelsolin is a well-studied calcium regulated
mediator of actin ﬁlament assembly and disassembly that
was previously identiﬁed as a target of caspase-3-mediated
apoptosis [39] and has previously been implicated in human
DCM [40]. Given that loss of gelsolin in a knockout mouse
line [41] results in reduced apoptosis in response to
myocardial infarction (artery ligation), which normally
induces severe hypertrophy and dilation, the up-regulation
of gelsolin (and other functionally related proteins) we
Figure 4. Signaling cluster and integrin signaling. Zoom-in of the Enrichment Map gene set cluster representing signaling pathways
enriched at the early and mid-stages of heart failure. A summary description of the cluster was visualized as a ‘‘term cloud’’ using Wordle
(http://www.wordle.net/) derived from the text descriptions of all gene sets. Term size indicates its frequency; thus, large terms best
summarize the cluster (i.e. signaling pathways). Speciﬁc terms related to the integrin pathway are highlighted within this cluster and in
the network.
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remodeling that precedes dilation (Fig. 2) and the increased
apoptosis observed during disease progression [7]. Gelsolin
is one of many factors downstream of caspase-3 that are
progressively up-regulated from early to mid-stage.
Conversely, negative apoptosis related signaling factors
appeared to be down-regulated. Most notable is an initial
up-regulation at early stage, followed by down regulation at
mid-stage, of the ubiquitin-protein ligase XIAP, a well-
known inhibitor of apoptosis [42] (Fig. 3). Again, this is
consistent with the overall gene set output showing a
progressive increase in apoptosis during tissue remodeling
and dilation.
Linked to apoptosis in the Enrichment Map is another
large cluster representing up-regulation of the cell cycle at
mid-stage disease. Although the gene set names are indi-
cative of cell cycle events (i.e. Reactome_APC/C-Mediated
degradation of cell cycle proteins), examination of the genes
indicates this cluster is dominated by the proteasome
complex, which is involved in multiple processes (including
apoptosis and cell cycle). The ubiquitin-proteasome
machinery is involved in the targeted cleavage and degra-
dation of signaling proteins and has been linked to apoptotic
cell death and the unfolded protein response previously seen
in R9C [43]. There are, however, conﬂicting reports as to
whether the proteasome is up- or down-regulated in cardiac
dysfunction [43]. From our current analysis, we see a clear
up-regulation of proteasome levels at mid-stage disease
connecting to apoptosis in the Enrichment Map. The rela-
tionship between these two processes can be better gleaned
from a more detailed mechanistic representation of the
underlying gene sets.
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Figure 5. Reduced mortality
and decreased MAPK activa-
tion with propanolol. (A)
Cardiac cellular lysates from
16-wk-old mice were collec-
ted and analyzed for MAPK
pathway activity (indicated
by JNK expression and
phosphorylation of p38 Map
kinase), and versus a control
(GAPDH). MAPK pathway is
overactive in PLN-R9C mice.
(B) Treating mice with
propanolol reduces activity
of MAPK pathway at 16 wk in
PLN-R9C mice compared to
wild type. (C) Sixteen-wk-old
mice were subjected to M-
mode echocardiography and
left ventricular end diastolic
dimension (LVEDD), left
ventricular end systolic
dimension (LVESD) and
fractional shortening (FS)
were assessed. Propanolol
treatment reduces LVEDD,
LVESD and fractional short-
ening to wild type levels. (D)
WT and PLN-R9C mice were
treated with/without propa-
nolol (0.5g/L in drinking
water) starting at 8wk of age.
Mortality was monitored in
all groups at 16wk. Cardiac
lysates and tissues were
obtained and analyzed as
previously described [7].
Antibodies used: phospho-
p38 – BD ]612281 from BD
bioscience and SAPK/JNK –
mAb ]9258 from Cell Signal-
ing.
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A more sparsely connected cluster of multiple regulatory
processes was found to be up-regulated to varying degrees at
early- and/or mid-stage disease (Fig. 4). This grouping
represents an assortment of interlinked pathways originat-
ing from different annotation databases. Integrin signaling
is one of the more enriched pathways (highlighted in Fig. 4),
with representations from three independent data sets
linked via a focal adhesion term, which is consistent with
the role of integrins as cell-adhesion receptors [44]. Integrins
also play a key role in sensing and transmitting mechanical
load in cardiomyoctyes [45], connecting the extracellular
matrix to intracellular signaling and the contractile appara-
tus (as can be seen by the connections between integrin
signaling and actin cytoskeleton regulation in the enrich-
ment map). In DCM, this process is involved in modifying
the core contractile machinery to compensate for impaired
calcium handling [45].
The MAP kinase signaling cascade is also prominently up-
regulated at mid-stage and represented by multiple terms,
including ‘‘Signaling to ERKS’’ (REACT_12058.1), ‘‘Prolon-
ged ERK activation events’’ (REACT_12005.1) and ‘‘MAPK
signaling’’ (KEGG:HSA04010) (Fig. 4). The MAPK (mitogen-
activated protein kinase) signaling pathway, and more speci-
ﬁcally up-regulation of p38 (MAPK14) [46] in rat myocytes,
has been shown to induce heart dilation. Similarly, the down-
regulation of the p38 [47] or JNK (MAPK8) [48] catalytic
subunits in transgenic mouse models followed by stress
induced through aortic banding has been previously shown to
induce cardiac hypertrophy leading to heart failure. In-depth
analysis of the components in the MAPK signaling gene set
from KEGG revealed that a handful of signiﬁcantly up-regu-
lated proteins and many additional weakly up-regulated
factors were obtained by proteomic proﬁling. We therefore
decided to focus on this group for targeted follow-up experi-
ments since members of the pathway, such as p38 and JNK,
have been previously linked to either hypertrophy or dilation
depending on the direction of their differential expression. We
examined the activation levels of the two key downstream
effectors of the MAPK pathway, p38 and JNK, as indicators of
pathway activity. As predicted from the GSEA results, both
p38 and JNK show elevated activity in 16-wk-old PLN-R9C
mutant mice as compared to wild-type controls (Fig. 5A), even
though these proteins were not signiﬁcantly up-regulated as
measured by the KS statistic.
To further investigate the role of the MAPK pathway in
mediating the progression to heart failure, we administered
the beta blocker propanolol to PLN-R9C mice, which is
commonly used clinically for treating heart failure [49] and
can result in the reduction of MAPK-dependent pathway
activation [50]. Beta blockers function initially as negative
ionotropic agents, decreasing the strength of muscle
contraction thereby reducing energy requirements and wall
stress [50]. As demonstrated in Fig. 5B, both p38 and JNK
returned to near wild-type levels at 16 wk after administra-
tion of propanolol starting at 8 wk. Further, phenotypic
examinations (Fig. 5C) and the mice survival curves
(Fig. 5D) also conﬁrmed nearly complete rescue of PLN-R9C
defect upon treatment with propanolol. These results imply
causal participation of MAPK signaling, whose activation
was missed in our initial proteomic assessment based on
simple ORA analysis [7].
4 Concluding remarks
Like other groups, we have been investigating the causal
basis for progressive DCM using an integrative proﬁling
approach incorporating data from multiple relevant
sources to generate a thorough, yet concise picture of the
underlying functional disturbances over time. By applying
GSEA to the early and mid-time points of DCM progression
using a large and diverse set of pathways and functional
annotations with an Enrichment Map display, we demon-
strated how proteins ranked by relative expression in cardiac
tissue in our PLN-R9C mouse model can be converted into a
global view of processes changing over the course of heart
disease progression, starting from pre-symptomatic pathol-
ogy to DCM. These additional analyses have revealed novel
functional connections, both between individual gene
products and across biological pathways and broader
systems, that were missed previously using simple ORA
analysis [7]. Our new method also more clearly shows
processes affected in common, or uniquely, at the early- and
mid-disease stages. These ranged from widespread effects
on central metabolism and cytoskeletal remodeling to more
speciﬁc perturbations in apoptotic, integrin and MAPK
signaling.
While many of the gene sets, such as metabolism and
actin remodeling, have been previously recognized in heart
disease studies, there are still unanswered questions as to
their mechanistic contributions to cardiac disease [51]. The
biological signiﬁcance of the metabolism shift is suggested
by recent publications indicating that it leads to a critical
tipping point in the heart where energy reserves are not
sufﬁcient to maintain function which ultimately leads to
failure [52]. Our re-analysis highlights an early increase in
energy demands by the heart manifested in the up-regula-
tion of NADH Dehydrogenase and ATP synthase. This up-
regulation is only detectable at an early stage when there is
minimal phenotypic indication of any contraction defect,
but disappears at mid-stage disease once the heart has
already begun to fail, adding additional weight to the above
tipping point interpretation.
The power of our method is that it can quickly identify
general processes that are interesting and then enables a
more detailed study, as can be seen from our analysis of
apoptosis and MAPK signaling. This approach is ﬂexible
and can be applied to other datasets. As other high-
throughput studies of DCM are conducted and gene set
curation efforts continue, a more complete network will be
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underlying molecular basis for progressive heart failure in
human patient populations. On-going efforts to improve the
coverage of pathway data, encompassing transcriptional
regulation by microRNAs and transcription factors [53–55],
will likely provide the basis for more robust and informative
computational analysis at the gene set and gene-interaction
level. Increased protein coverage by MS and more sensitive
methods will further expand the number of enriched
gene sets, which may otherwise be missed due to too few
differential proteins being present. The framework proposed
here constitutes an ideal staging ground for more advanced
computational tools supporting visualization, analysis and
hypothesis generation for protein expression data. Although
challenging, using pathway analysis to decipher the
mechanism of a complex disease such as DCM facilitates
the development of a more coherent molecular under-
standing of DCM etiologies and potentially other cardio-
vascular diseases that lead to heart failure.
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